Author

Silvio Danese

A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING
A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING

Silvio Danese  et al.

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Silvio Danese  et al.

EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Silvio Danese  et al.

INVESTIGATING THE ROLE OF GUT EUKARYOTIC VIROME IN CONTRIBUTING TO COLORECTAL CANCER CARCINOGENESIS
INVESTIGATING THE ROLE OF GUT EUKARYOTIC VIROME IN CONTRIBUTING TO COLORECTAL CANCER CARCINOGENESIS

Silvio Danese  et al.

THE ROLE OF MFSD2A IN THE RESOLUTION OF COLORECTAL CANCER-PROMOTING INFLAMMATION: IMPLICATIONS FOR INNOVATIVE THERAPIES
THE ROLE OF MFSD2A IN THE RESOLUTION OF COLORECTAL CANCER-PROMOTING INFLAMMATION: IMPLICATIONS FOR INNOVATIVE THERAPIES

Silvio Danese  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Silvio Danese  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Silvio Danese  et al.

THE CAUDOVIRALES CLASS OF VIRUSES IS ASSOCIATED WITH DENDRITIC CELL IMPAIRMENT IN CD PATIENTS​​​​
THE CAUDOVIRALES CLASS OF VIRUSES IS ASSOCIATED WITH DENDRITIC CELL IMPAIRMENT IN CD PATIENTS​​​​

Silvio Danese  et al.

BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Silvio Danese  et al.

A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR
A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR

Silvio Danese  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese  et al.

ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDING METAL STENT (SEMS) IN THE TREATMENT OF NON-LARGE ANASTOMOTIC DEHISCENCES AFTER ONCOLOGIC IVOR-LEWIS ESOPHAGECTOMY: A MATCHED CASE-CONTROL STUDY
ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDING METAL STENT (SEMS) IN THE TREATMENT OF NON-LARGE ANASTOMOTIC DEHISCENCES AFTER ONCOLOGIC IVOR-LEWIS ESOPHAGECTOMY: A MATCHED CASE-CONTROL STUDY

Silvio Danese  et al.

TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA
TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Silvio Danese  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Silvio Danese  et al.

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Silvio Danese  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Silvio Danese  et al.

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS
ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Silvio Danese  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Silvio Danese  et al.

G-POEM FOR REFRACTORY GASTROPARESIS: BASAL SYMPTOM SEVERITY AND INTRAGASTRIC MEAL DISTRIBUTION DURING GASTRIC EMPTYING SCINTIGRAPHY MAY BE PREDICTORS OF 12-MONTH CLINICAL OUTCOME
G-POEM FOR REFRACTORY GASTROPARESIS: BASAL SYMPTOM SEVERITY AND INTRAGASTRIC MEAL DISTRIBUTION DURING GASTRIC EMPTYING SCINTIGRAPHY MAY BE PREDICTORS OF 12-MONTH CLINICAL OUTCOME

Silvio Danese  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Silvio Danese  et al.

Item 81 - 100 / 122
1 2 3 4
5
6 7